Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trial
Keystone Symposia
presentation
First-in-Class FASN Inhibitor Denifanstat Achieved All Endpoints in the Treatment of Acne Vulgaris: Results from a Phase 3 Randomised Placebo Controlled Trial
European Academy of Dermatology and Venereology (EADV) Congress 2025
